Cargando…

A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab

Psoriasis is a chronic and debilitating inflammatory immune-mediated skin disorder. Several cytokines including interleukin (IL)-23 were demonstrated to play a central role in the pathogenesis of this disease. Treatment options for psoriasis range from topical to systemic modalities, depending on th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghazawi, Feras M., Mahmood, Farhan, Kircik, Leon, Poulin, Yves, Bourcier, Marc, Vender, Ronald, Wiseman, Marni C., Lynde, Charles, Litvinov, Ivan V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8383205/ https://www.ncbi.nlm.nih.gov/pubmed/34447766 http://dx.doi.org/10.3389/fmed.2021.702776

Ejemplares similares

Erythrodermic psoriasis improved by Tildrakizumab
por: Trevisan, Giampaolo, et al.
Publicado: (2022)

Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disorders
por: Gooderham, M.J., et al.
Publicado: (2018)

Tildrakizumab in the treatment of psoriasis – literature review
por: Banaszczyk, Katarzyna
Publicado: (2019)

Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice
por: Ruggiero, A., et al.
Publicado: (2021)

Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy
por: Pithadia, Deeti J., et al.
Publicado: (2019)

Tildrakizumab: A new therapeutic option for erythrodermic psoriasis?
por: Megna, Matteo, et al.
Publicado: (2021)

Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers
por: Vender, Ronald B., et al.
Publicado: (2022)

Editorial: The Emerging Role of Artificial Intelligence in Dermatology
por: Mahmood, Farhan, et al.
Publicado: (2021)

Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis
por: Le, Michelle, et al.
Publicado: (2021)

Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
por: Burlando, Martina, et al.
Publicado: (2021)

A Case of Concurrent Psoriasis and Hidradenitis Suppurativa Successfully Treated with Tildrakizumab
por: Damsin, Thomas
Publicado: (2023)

Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology
por: Papp, Kim A., et al.
Publicado: (2021)

Psoriasis Prevalence and Severity by Expert Elicitation
por: Papp, Kim A., et al.
Publicado: (2021)

Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis)
por: Narcisi, Alessandra, et al.
Publicado: (2022)

Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
por: Beck, Kristen M, et al.
Publicado: (2018)

Erratum: Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting
Publicado: (2021)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Long term efficacy, safety, and tolerability of tildrakizumab in epileptic patient with psoriasis and eczema
por: Bernardini, Nicoletta, et al.
Publicado: (2022)

Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE
por: Papp, K.A., et al.
Publicado: (2015)

Incidence of serious gastrointestinal events among tildrakizumab‐treated patients with psoriasis: Letter to the Editor
por: Gooderham, M., et al.
Publicado: (2019)

Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis
por: Galluzzo, Marco, et al.
Publicado: (2022)

Tildrakizumab in moderate‐to‐severe plaque psoriasis: A multicenter, retrospective, real‐life study
por: Caldarola, Giacomo, et al.
Publicado: (2022)

Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
por: Bai, Fan, et al.
Publicado: (2019)

Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
por: Näslund-Koch, Charlotte, et al.
Publicado: (2020)

A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE)
por: Papp, KA, et al.
Publicado: (2015)

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
por: Ruggiero, Angelo, et al.
Publicado: (2023)

Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis
por: Di Brizzi, Eugenia Veronica, et al.
Publicado: (2023)

Tildrakizumab ineffective in generalized granuloma annulare
por: Song, Eingun James
Publicado: (2020)

The role of IL-23 in the immunopathogenesis of psoriasis
por: Meglio, Paola Di, et al.
Publicado: (2010)

Enhanced Effectiveness of Adalimumab Compared to Topical/Traditional Systemic Agents in the Treatment of Moderate to Severe Plaque Psoriasis: Results from a Canadian Observational Epidemiologic Study (COMPLETE-PS)
por: Lynde, Charles W., et al.
Publicado: (2022)

The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque Psoriasis
por: Carrico, Justin, et al.
Publicado: (2020)

Clearance of head and neck involvement in plaque psoriasis with tildrakizumab treatment in the phase 3 reSURFACE 1 study
por: Menter, M.A., et al.
Publicado: (2020)

A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis
por: Becher, Gabrielle, et al.
Publicado: (2022)

Efficacy of Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis in the North American Subgroup of Patients: Pooled Analysis of Four Phase 3 Studies
por: Pariser, David, et al.
Publicado: (2017)

Targeting IL-23 in psoriasis: current perspectives
por: Fotiadou, Christina, et al.
Publicado: (2018)

A Review of the Clinical Trial Landscape in Psoriasis: An Update for Clinicians
por: Drakos, Anastasia, et al.
Publicado: (2022)

Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel
por: Papp, Kim A., et al.
Publicado: (2022)

Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab
por: Kimball, A.B., et al.
Publicado: (2019)

Tildrakizumab: Successful Response in Two Patients With Psoriatic Arthritis
por: Buononato, Dario, et al.
Publicado: (2022)

Correction to: Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel
por: Papp, Kim A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jaisehh3pl2qc1inuck47sqltk